Taigen Biotechnology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Taigen Biotechnology - overview
Established
2001
Location
Taipei, -, Taiwan - China
Primary Industry
Biotechnology
About
Based in Taipei, China, and founded in 2001, Taigen Biotechnology operates as a research-based and product-driven pharmaceutical company, dedicated to the development of anti-infective drugs. The company has set up a branch office in Beijing. There are 70 employees in the company, and 80% of them are the research and development staff. The CEO, Guolong Huang, worked at Sandoz, Novartis AG.
In July 2001, it raised strategic investment from a new investor National Development Fund of the Executive Yuan. In January 2009, Taigen Biotechnology raised USD 37 million in series C funding led by returning investor MPM Capital with participation from new investor Taiwan Sugar Corporation and returning investor YFY Global Investment (BVI). The company specializes in the development of drugs for anti-infective diseases. Its main products are TG-1000, Burixafor, NEMONOXACIN, and Flarevir.
NEMONOXACIN is effective against drug-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and AB bacteria. Furaprevir can work against 6 genotypes of the hepatitis C virus. The drugs can be used in the treatment of liver disease, infectious diseases, and tumors.
Current Investors
CDIB Capital Group, YFY Global Investment, GAINS Investment Corporation
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Epidemiology, Pharmaceutical Research & Development
Website
www.taigenbiotech.com.tw
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.